/
Cardiovascular
Myocardial Infarction
77
Pipeline Programs↗
126
Active Trials↗
50
Companies Involved↗
Myocardial Infarction is a moderately active landscape with 77 programs across 50 companies. The most active players are Amgen, ResoTher Pharma, Novartis. 22 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical48
Phase 11
Phase 26
Phase 322
Approved
No programs
Analysis
Modality Breakdown
93%
Small molecule
64 of 69 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 69 classified programs, each share of the total. Modality classified for 99% of 77 pipeline programs.
Analysis
Trial Status
504
clinical trials
Completed261 · 52%
Unknown status75 · 15%
Recruiting67 · 13%
Not yet recruiting30 · 6%
Active, not recruiting27 · 5%
Withdrawn21 · 4%
Other23 · 5%
Clinical Trials
Trial Activity
504 trials
Percutaneous Coronary Intervention With or Without Manual Thrombus Aspiration in Patients With ST-Segment Elevation Myocardial Infarction and Angiographically Evident Thrombus
Recruiting·—·Preclinical·NCT06654453·3,500 enrolled
Strategies for Antiplatelet Management Following Acute Coronary Syndrome
Recruiting·IInstituto de Investigación Sanitaria de la Fundación Jiménez Díaz·Approved·NCT07507500·8,100 enrolled
SUBDIMA Study: Subclinical Depression in Myocardial Infarction -Prevalence, Predictors and Prognostic Impact.
Recruiting·FFondazione Policlinico Universitario Agostino Gemelli IRCCS·Preclinical·NCT07492537·100 enrolled
Page 1 of 34
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)